{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:16:33Z","timestamp":1792808193193,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2500300"],"award-info":[{"award-number":["2021YFC2500300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81830005"],"award-info":[{"award-number":["81830005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-041"],"award-info":[{"award-number":["2021-I2M-1-041"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s13402-024-00971-5","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T14:02:00Z","timestamp":1721052120000},"page":"1879-1895","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells"],"prefix":"10.1007","volume":"47","author":[{"given":"Zhifeng","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runxia","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianci","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaowei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"key":"971_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"C.D. DiNardo","year":"2020","unstructured":"C.D. DiNardo, B.A. Jonas, V. Pullarkat, et al., Azacitidine and Venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383, 617\u2013629 (2020)","journal-title":"N. Engl. J. Med."},{"key":"971_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"S.L. Maude","year":"2018","unstructured":"S.L. Maude, T.W. Laetsch, J. Buechner, et al., Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018)","journal-title":"N. Engl. J. Med."},{"key":"971_CR3","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"S.S. Neelapu","year":"2017","unstructured":"S.S. Neelapu, F.L. Locke, N.L. Bartlett, et al., Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017)","journal-title":"N. Engl. J. Med."},{"key":"971_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrc3670","volume":"14","author":"P.G. Coulie","year":"2014","unstructured":"P.G. Coulie, B.J. Van den Eynde, P. van der Bruggen, T. Boon, Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat. Rev. Cancer 14, 135\u2013146 (2014)","journal-title":"Nat. Rev. Cancer"},{"key":"971_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.4049\/jimmunol.1701155","volume":"200","author":"S. Srivastava","year":"2018","unstructured":"S. Srivastava, S.R. Riddell, Chimeric antigen receptor T cell therapy: challenges to bench-to-bedside efficacy. J. Immunol. 200, 459\u2013468 (2018)","journal-title":"J. Immunol."},{"key":"971_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41551-020-00625-5","volume":"5","author":"G. Xie","year":"2021","unstructured":"G. Xie, N.A. Ivica, B. Jia, et al., CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia. Nat. Biomed. Eng. 5, 399\u2013413 (2021)","journal-title":"Nat. Biomed. Eng."},{"key":"971_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/14712598.2023.2174015","volume":"23","author":"G. Ciotti","year":"2023","unstructured":"G. Ciotti, G. Marconi, A. Sperotto, M.B. Giannini, M. Gottardi, G. Martinelli, Biological therapy in elderly patients with acute myeloid leukemia. Expert Opin. Biol. Ther. 23, 175\u2013194 (2023)","journal-title":"Expert Opin. Biol. Ther."},{"key":"971_CR8","first-page":"1490","volume":"7","author":"P.F. Bross","year":"2001","unstructured":"P.F. Bross, J. Beitz, G. Chen, et al., Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7, 1490\u20131496 (2001)","journal-title":"Clin. Cancer Res."},{"key":"971_CR9","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1038\/leu.2017.187","volume":"31","author":"C.D. Godwin","year":"2017","unstructured":"C.D. Godwin, R.P. Gale, R.B. Walter, Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia 31, 1855\u20131868 (2017)","journal-title":"Leukemia"},{"key":"971_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.exphem.2017.06.007","volume":"54","author":"A.A. Laing","year":"2017","unstructured":"A.A. Laing, C.J. Harrison, B.E.S. Gibson, K. Keeshan, Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia. Exp. Hematol. 54, 40\u201350 (2017)","journal-title":"Exp. Hematol."},{"key":"971_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.blre.2014.04.001","volume":"28","author":"G.S. Laszlo","year":"2014","unstructured":"G.S. Laszlo, E.H. Estey, R.B. Walter, The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood. Rev. 28, 143\u2013153 (2014)","journal-title":"Blood. Rev."},{"key":"971_CR12","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"R.A. Gardner","year":"2017","unstructured":"R.A. Gardner, O. Finney, C. Annesley, et al., Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129, 3322\u20133331 (2017)","journal-title":"Blood"},{"key":"971_CR13","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1172\/JCI87366","volume":"126","author":"M. Ruella","year":"2016","unstructured":"M. Ruella, D.M. Barrett, S.S. Kenderian, et al., Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J. Clin. Invest. 126, 3814\u20133826 (2016)","journal-title":"J. Clin. Invest."},{"key":"971_CR14","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1200\/JCO.21.01405","volume":"40","author":"R.M. Myers","year":"2022","unstructured":"R.M. Myers, A. Taraseviciute, S.M. Steinberg, et al., Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J. Clin. Oncol. 40, 932\u2013944 (2022)","journal-title":"J. Clin. Oncol."},{"key":"971_CR15","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L. Labanieh","year":"2023","unstructured":"L. Labanieh, C.L. Mackall, CAR immune cells: design principles, resistance and the next generation. Nature 614, 635\u2013648 (2023)","journal-title":"Nature"},{"key":"971_CR16","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/ijc.33865","volume":"150","author":"Y. Liu","year":"2022","unstructured":"Y. Liu, S. Wang, M.L. Schubert, et al., CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. Int. J. Cancer 150, 1141\u20131155 (2022)","journal-title":"Int. J. Cancer"},{"key":"971_CR17","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/mt.2014.164","volume":"23","author":"Q.S. Wang","year":"2015","unstructured":"Q.S. Wang, Y. Wang, H.Y. Lv, et al., Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol. Ther. 23, 184\u2013191 (2015)","journal-title":"Mol. Ther."},{"key":"971_CR18","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1182\/blood.V79.7.1811.1811","volume":"79","author":"I.D. Bernstein","year":"1992","unstructured":"I.D. Bernstein, J.W. Singer, F.O. Smith, et al., Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia. Blood 79, 1811\u20131816 (1992)","journal-title":"Blood"},{"key":"971_CR19","doi-asserted-by":"publisher","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","volume":"119","author":"R.B. Walter","year":"2012","unstructured":"R.B. Walter, F.R. Appelbaum, E.H. Estey, I.D. Bernstein, Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 119, 6198\u20136208 (2012)","journal-title":"Blood"},{"key":"971_CR20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41375-021-01375-2","volume":"36","author":"Y. Xu","year":"2022","unstructured":"Y. Xu, J. Mou, Y. Wang, et al., Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway. Leukemia 36, 403\u2013415 (2022)","journal-title":"Leukemia"},{"key":"971_CR21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41408-021-00536-x","volume":"11","author":"N. Chen","year":"2021","unstructured":"N. Chen, Y. Xu, J. Mou, et al., Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. Blood Cancer J. 11, 144 (2021)","journal-title":"Blood Cancer J."},{"key":"971_CR22","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1182\/blood-2013-09-527044","volume":"123","author":"G.S. Laszlo","year":"2014","unstructured":"G.S. Laszlo, C.J. Gudgeon, K.H. Harrington, et al., Cellular determinants for preclinical activity of a novel CD33\/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood 123, 554\u2013561 (2014)","journal-title":"Blood"},{"key":"971_CR23","first-page":"376","volume":"43","author":"T. Zhang","year":"2022","unstructured":"T. Zhang, M.L. Chen, X.Y. Liu, et al., [Preparation of CD33 targeted bispecific- and trispecific-T cell engagers and their cytotoxicity on leukemia cells]. Zhonghua Xue Ye Xue Za Zhi 43, 376\u2013382 (2022)","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"971_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1158\/1538-7445.AM2017-55","volume":"77","author":"T.L. Arvedson","year":"2017","unstructured":"T.L. Arvedson, M. Balazs, P. Bogner, et al., Abstract 55: generation of half-life extended anti-CD33 BiTE\u00ae antibody constructs compatible with once-weekly dosing. Cancer Res. 77, 55\u201355 (2017)","journal-title":"Cancer Res."},{"key":"971_CR25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1146\/annurev-med-060512-150254","volume":"65","author":"D.M. Barrett","year":"2014","unstructured":"D.M. Barrett, N. Singh, D.L. Porter, S.A. Grupp, C.H. June, Chimeric antigen receptor therapy for cancer. Annu. Rev. Med. 65, 333\u2013347 (2014)","journal-title":"Annu. Rev. Med."},{"key":"971_CR26","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","volume":"9","author":"U. Brinkmann","year":"2017","unstructured":"U. Brinkmann, R.E. Kontermann, The making of bispecific antibodies. MAbs 9, 182\u2013212 (2017)","journal-title":"MAbs"},{"key":"971_CR27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2174\/1566523013348418","volume":"1","author":"L. Alvarez-Vallina","year":"2001","unstructured":"L. Alvarez-Vallina, Genetic approaches for antigen-selective cell therapy. Curr. Gene Ther. 1, 385\u2013397 (2001)","journal-title":"Curr. Gene Ther."},{"key":"971_CR28","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.4049\/jimmunol.171.2.1070","volume":"171","author":"B. Blanco","year":"2003","unstructured":"B. Blanco, P. Holliger, R.G. Vile, L. Alvarez-Vallina, Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells. J. Immunol. 171, 1070\u20131077 (2003)","journal-title":"J. Immunol."},{"key":"971_CR29","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","volume":"37","author":"B.D. Choi","year":"2019","unstructured":"B.D. Choi, X. Yu, A.P. Castano, et al., CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat. Biotechnol. 37, 1049\u20131058 (2019)","journal-title":"Nat. Biotechnol."},{"key":"971_CR30","doi-asserted-by":"publisher","first-page":"E2068","DOI":"10.1073\/pnas.1716266115","volume":"115","author":"A.J. Davenport","year":"2018","unstructured":"A.J. Davenport, R.S. Cross, K.A. Watson, et al., Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. Proc. Natl. Acad. Sci. U. S. A. 115, E2068\u2013e2076 (2018)","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"971_CR31","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","volume":"173","author":"M.Y. Kim","year":"2018","unstructured":"M.Y. Kim, K.R. Yu, S.S. Kenderian, et al., Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell 173, 1439\u20131453.e1419 (2018)","journal-title":"Cell"},{"key":"971_CR32","doi-asserted-by":"publisher","first-page":"10638","DOI":"10.18632\/oncotarget.7079","volume":"7","author":"N. An","year":"2016","unstructured":"N. An, Z. Tao, S. Li, et al., Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells. Oncotarget 7, 10638\u201310649 (2016)","journal-title":"Oncotarget"},{"key":"971_CR33","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1089\/hum.2017.241","volume":"29","author":"S. Li","year":"2018","unstructured":"S. Li, Z. Tao, Y. Xu, et al., CD33-specific chimeric antigen receptor T cells with different co-stimulators showed potent anti-leukemia efficacy and different phenotype. Hum. Gene Ther. 29, 626\u2013639 (2018)","journal-title":"Hum. Gene Ther."},{"key":"971_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40164-023-00423-0","volume":"12","author":"M. Chen","year":"2023","unstructured":"M. Chen, X. Liu, N. Peng, et al., Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy. Exp. Hematol. Oncol. 12, 64 (2023)","journal-title":"Exp. Hematol. Oncol."},{"key":"971_CR35","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","volume":"6","author":"K. Li","year":"2021","unstructured":"K. Li, H. Shi, B. Zhang, et al., Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct. Target. Ther. 6, 362 (2021)","journal-title":"Signal Transduct. Target. Ther."},{"key":"971_CR36","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/ncomms12150","volume":"7","author":"V. Bronte","year":"2016","unstructured":"V. Bronte, S. Brandau, S.H. Chen, et al., Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat. Commun. 7, 12150 (2016)","journal-title":"Nat. Commun."},{"key":"971_CR37","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","volume":"129","author":"F. Braig","year":"2017","unstructured":"F. Braig, A. Brandt, M. Goebeler, et al., Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood 129, 100\u2013104 (2017)","journal-title":"Blood"},{"key":"971_CR38","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"J.N. Brudno","year":"2019","unstructured":"J.N. Brudno, J.N. Kochenderfer, Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood. Rev. 34, 45\u201355 (2019)","journal-title":"Blood. Rev."},{"key":"971_CR39","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","volume":"11","author":"H. Qin","year":"2018","unstructured":"H. Qin, S. Ramakrishna, S. Nguyen, et al., Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22. Mol. Ther. Oncolytics 11, 127\u2013137 (2018)","journal-title":"Mol. Ther. Oncolytics"},{"key":"971_CR40","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","volume":"27","author":"S. Cordoba","year":"2021","unstructured":"S. Cordoba, S. Onuoha, S. Thomas, et al., CAR T\u2009cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B\u2009cell acute lymphoblastic leukemia: a phase 1 trial. Nat. Med. 27, 1797\u20131805 (2021)","journal-title":"Nat. Med."},{"key":"971_CR41","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1080\/16078454.2022.2074704","volume":"27","author":"Z. Shi","year":"2022","unstructured":"Z. Shi, Y. Zhu, J. Zhang, B. Chen, Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia. Hematology 27, 642\u2013652 (2022)","journal-title":"Hematology"},{"key":"971_CR42","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/mt.2014.156","volume":"23","author":"K. Iwahori","year":"2015","unstructured":"K. Iwahori, S. Kakarla, M.P. Velasquez, et al., Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. Mol. Ther. 23, 171\u2013178 (2015)","journal-title":"Mol. Ther."},{"key":"971_CR43","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.it.2019.01.008","volume":"40","author":"B. Blanco","year":"2019","unstructured":"B. Blanco, M. Compte, S. Lykkemark, L. Sanz, L. Alvarez-Vallina, T Cell-redirecting strategies to \u2018STAb\u2019 tumors: beyond CARs and bispecific antibodies. Trends Immunol. 40, 243\u2013257 (2019)","journal-title":"Trends Immunol."},{"key":"971_CR44","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ymthe.2022.05.011","volume":"30","author":"Y. Yin","year":"2022","unstructured":"Y. Yin, J.L. Rodriguez, N. Li, et al., Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors. Mol. Ther. 30, 2537\u20132553 (2022)","journal-title":"Mol. Ther."},{"key":"971_CR45","doi-asserted-by":"publisher","first-page":"e430","DOI":"10.1038\/bcj.2016.38","volume":"6","author":"X. Liu","year":"2016","unstructured":"X. Liu, D.M. Barrett, S. Jiang, et al., Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice. Blood Cancer J. 6, e430 (2016)","journal-title":"Blood Cancer J."},{"key":"971_CR46","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1038\/mt.2016.116","volume":"24","author":"C.L. Bonifant","year":"2016","unstructured":"C.L. Bonifant, A. Szoor, D. Torres, et al., CD123-engager T cells as a novel immunotherapeutic for acute myeloid leukemia. Mol. Ther. 24, 1615\u20131626 (2016)","journal-title":"Mol. Ther."},{"key":"971_CR47","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.ymthe.2020.02.016","volume":"28","author":"C.E. Porter","year":"2020","unstructured":"C.E. Porter, A. Rosewell Shaw, Y. Jung, et al., Oncolytic adenovirus armed with BiTE, cytokine, and checkpoint inhibitor enables CAR T cells to control the growth of heterogeneous tumors. Mol. Ther. 28, 1251\u20131262 (2020)","journal-title":"Mol. Ther."},{"key":"971_CR48","doi-asserted-by":"publisher","first-page":"e2206856","DOI":"10.1002\/advs.202206856","volume":"10","author":"S.W. Huang","year":"2023","unstructured":"S.W. Huang, C.M. Pan, Y.C. Lin, et al., BiTE-secreting CAR-\u03b3\u03b4T as a dual targeting strategy for the treatment of solid tumors. Adv. Sci. (Weinh) 10, e2206856 (2023)","journal-title":"Adv. Sci. (Weinh)"},{"key":"971_CR49","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"R.G. Majzner","year":"2018","unstructured":"R.G. Majzner, C.L. Mackall, Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219\u20131226 (2018)","journal-title":"Cancer Discov."},{"key":"971_CR50","doi-asserted-by":"publisher","first-page":"2054106","DOI":"10.1080\/2162402X.2022.2054106","volume":"11","author":"\u00c1. Ram\u00edrez-Fern\u00e1ndez","year":"2022","unstructured":"\u00c1. Ram\u00edrez-Fern\u00e1ndez, \u00d3. Aguilar-Sope\u00f1a, L. D\u00edez-Alonso, et al., Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies. Oncoimmunology 11, 2054106 (2022)","journal-title":"Oncoimmunology"},{"key":"971_CR51","doi-asserted-by":"crossref","unstructured":"Y. Zhao, J. Chen, M. Andreatta, et al., IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat. Biotechnol. (2024)","DOI":"10.1038\/s41587-023-02060-8"},{"key":"971_CR52","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.it.2003.12.001","volume":"25","author":"L. Sanz","year":"2004","unstructured":"L. Sanz, B. Blanco, L. Alvarez-Vallina, Antibodies and gene therapy: teaching old \u2018magic bullets\u2019 new tricks. Trends Immunol. 25, 85\u201391 (2004)","journal-title":"Trends Immunol."},{"key":"971_CR53","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1007\/s00262-023-03529-w","volume":"72","author":"S.S. Mun","year":"2023","unstructured":"S.S. Mun, J. Meyerberg, L. Peraro, et al., Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1. Cancer Immunol. Immunother. 72, 3773\u20133786 (2023)","journal-title":"Cancer Immunol. Immunother."},{"key":"971_CR54","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1182\/bloodadvances.2020001792","volume":"5","author":"M. Subklewe","year":"2021","unstructured":"M. Subklewe, BiTEs better than CAR T cells. Blood Adv. 5, 607\u2013612 (2021)","journal-title":"Blood Adv."},{"key":"971_CR55","doi-asserted-by":"crossref","unstructured":"F. Ravandi, M. Subklewe, R.B. Walter, et al., Safety and tolerability of AMG 330 in adults with relapsed\/refractory AML: a phase 1a dose-escalation study. Leuk. Lymphoma, 1\u201311 (2024)","DOI":"10.1080\/10428194.2024.2346755"},{"key":"971_CR56","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13045-020-00953-8","volume":"13","author":"R. Gu","year":"2020","unstructured":"R. Gu, F. Liu, D. Zou, et al., Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia. J. Hematol. Oncol. 13, 122 (2020)","journal-title":"J. Hematol. Oncol."}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-024-00971-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-024-00971-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-024-00971-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T16:12:20Z","timestamp":1728576740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-024-00971-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["971"],"URL":"https:\/\/doi.org\/10.1007\/s13402-024-00971-5","relation":{},"ISSN":["2211-3428","2211-3436"],"issn-type":[{"value":"2211-3428","type":"print"},{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]},"assertion":[{"value":"1 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by the ethical committee in the Institute of Hematology and Blood Diseases Hospital, and all procedures were in accordance with the Helsinki Declaration. Written informed consent was obtained from each participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}